B-cell Maturation Antigen (BCMA) CAR-T cell therapy demonstrates a therapeutic role in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), primarily relying on the targeted clearance of plasmablasts and plasma cells expressing B-cell Maturation Antigen (BCMA). The gene discussed is TNFRSF17; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.